ABSTRACT
BACKGROUND: Transcatheter edge-to-edge repair (TEER) is a prominent therapeutic option for mitral regurgitation (MR) patients. However, it lacks objective parameters to assess procedural efficacy. This study aims to investigate the pulmonary venous (PV) flow as a surrogate for valvular hemodynamics and its associations to clinical outcomes. METHODS: Consecutive MR patients who underwent TEER in our center from 01/2020-10/2021 were retrospectively investigated. PV flow parameters were measured before and after TEER, including velocity (cm/s), velocity time integral (VTI) (cm) and systolic/diastolic ratios. Primary outcomes were 1, 6, and 12 months heart failure hospitalizations (HFH) and 1 year all-cause mortality. RESULTS: The cohort consisted of 80 patients. The mean age was 74.76±10.13 years, 26 with primary and 54 with secondary MR. Systolic wave parameters improved significantly after TEER: mean peak-velocity increased from 9.94±31.95 to 35.74±15.03 cm/s, and VTI from 3.62±5.99 to 8.33±4.72 cm. Furthermore, systolic to diastolic VTI and peak-velocities ratios showed significant improvement 0.39±0.63 to 0.81±0.47 and 0.23±0.66 to 0.91±0.43 respectively. Using multivariable analysis, higher post-procedural SVTI was associated with less HFH: 1-month (OR=0.72,CI[0.52,0.98]), 6-months (OR=0.8,CI[0.66,0.97]), 1-year (OR=0.85,CI[0.73,0.99]), as well as reduced 1-year mortality (OR=0.64 95% CI[0.45,0.91]). Furthermore, compared to patients with SVTI≥3, patients with SVTI<3 had higher risk for HFH at: 1-month (OR=16.59,CI[1.48,186.02]), 6-months (OR=12.2,CI[1.69,88.07]), and 1-year (OR=8.61,CI[1.27,58.27]), as well as elevated 1-year mortality (OR=8.07, 95% CI[1.04,62.28]). CONCLUSIONS: PV flow was significantly improved following TEER, and several hemodynamic parameters were associated HFH and mortality. These results may offer a basis for establishing future procedural goals to ensure better clinical outcomes.
ABSTRACT
The mitral valve (MV) plays an important role in the pathophysiology of hypertrophic obstructive cardiomyopathy (HOCM). Dynamic left ventricular outflow tract (LVOT) obstruction, caused by systolic anterior motion (SAM), is a common occurrence in most patients with hypertrophic cardiomyopathy and is directly associated with the MV apparatus. First line therapy for HOCM patients is pharmacological, and surgical intervention is often indicated for patients who do not respond to medical therapy. Emerging research on mitral disease in HOCM, specifically mitral regurgitation (MR), demonstrates that these patients frequently do not respond to standard therapeutic options, and can benefit from MV interventions. In this review, we describe the involvement of the MV in the pathogenesis of HOCM, discuss medical therapy, and explore available mitral procedures. Surgical myectomy, often combined with various modifications to the MV apparatus, is frequently necessary to achieve a durable resolution of LVOT obstruction and SAM-related MR. Alcohol septal ablation, an alternative to surgical myectomy, will be briefly mentioned. We also emphasize the role of transcatheter edge-to-edge repair (TEER) as a promising and novel therapeutic option for HOCM patients. Over time, TEER has established itself as an effective and safe procedure, demonstrating success across a spectrum of anatomical variations. The leaflet modification and movement restriction achieved through TEER help reduce SAM and, consequently, have the potential to alleviate LVOT obstruction and SAM-related MR. Furthermore, we propose a treatment algorithm for cases where TEER is a potential course of action for patients who are at high risk for other interventions.
